Pharma R&D spending remains in doldrums

July 2008
CMAJ: Canadian Medical Association Journal;7/29/2008, Vol. 179 Issue 3, p227
Academic Journal
The article provides information on the report of the Patented Medicines Prices Review Board that the pharmaceutical industry spending on research and development (R&D) in Canada continues to fall. The decline is below the 10 percent sales level promised when drug patent protection was extended in 1987. According to the report, the industry in 2007, spent about $259 million on basic research compared to clinical trials, availability studies, and drug regulation submission. The report also showed that there has been a little change in the overall nature of R&D expenditures.


Related Articles

  • A Swift Predominance of Ex-U.S. Sites. Getz, Kenneth A. // Applied Clinical Trials;Dec2005, Vol. 14 Issue 12, p21 

    The article reports that many pharmaceutical and biotechnology companies in the U.S. are using ex-U.S.-based investigative sites for their clinical trials. Some of the reasons for such trials are that trials overseas are less expensive and physicians there are eager to serve as investigators and...

  • Heart Drug Trial Halted. Hampton, Tracy // JAMA: Journal of the American Medical Association;1/24/2007, Vol. 297 Issue 4, p354 

    The article states that the U.S. Food and Drug Administration has announced that the pharmaceutical company Pfizer Inc. has stopped its phase 3 clinical trial that evaluated an investigational cardiovascular therapy called torcetrapib/atorvastatin. The trial was halted due to an increased rate...

  • Credible Lit. Baiter, Wendy; Scott, Marsha // Pharmaceutical Executive;Aug2006, Vol. 26 Issue 8, p138 

    The article focuses on several developments in report publications in the pharmaceutical industry in the U.S. Review article development is moving together with the most forward-thinking companies developing internal guidelines that leave content development to the author. Another development is...

  • Commentary: Why industry should register and disclose results of clinical studies--perspective of a recovering academic. Berlin, Jesse A. // BMJ: British Medical Journal (International Edition);4/23/2005, Vol. 330 Issue 7497, p959 

    Offers a discussion about why the pharmaceutical industry should register and disclose the results of clinical trials. Discussion of factors affecting publications; Demonstration of publication bias; Role of the author in a pharmaceutical research and development group; Question of whether early...

  • BIOSIMULATION: ADVANCEMENT IN THE PATHWAY OF DRUG DISCOVERY AND DEVELOPMENT. Aslam, Siddiqui; Bakde, B. V.; Channawar, M. A.; Chandewar, A. V. // International Journal of Pharmaceutical Sciences Review & Resear;Jul-Aug2010, Vol. 3 Issue 2, p99 

    The process of drug discovery from discovering a new drug molecule to registering it for marketing and commercialization are very complex and lengthy. The huge amount, a long period of time, and the clinical trials are required before a drug to be registered for human use. Nowadays there is...

  • Rapidly rising clinical trial costs worry researchers.  // CMAJ: Canadian Medical Association Journal;2/3/2009, Vol. 180 Issue 3, p277 

    The article reports on the rapid increase in the cost of conducting clinical trials. According to the Tuft Center for the Study of Drug Development, the clinical trial cost of drug development in the 1980s and the 1990s has increased five times faster than preclinical cost. It is said that...

  • MEDICINE'S SECRET STAT. Lemonick, Michael D. // Time;2/26/2007, Vol. 169 Issue 9, p54 

    This article discusses the statistical, medical practice of number needed to treat (NNT). The system is designed to find out how many people need to be treated to effectively treat one person. The practice is used in clinical trials of a drug or a procedure. Public health officials and...

  • Malaria: Joint attack on malaria. Ellis, Clare // Nature Reviews Microbiology;Sep2004, Vol. 2 Issue 9, p689 

    The article reports on the success of the study conducted by a group of international scientists that to develop a new antimalarial drug. The team, that is consists of researchers from universities and medical-related institutions worldwide, aims to identify a new synthetic peroxide antimalarial...

  • ENHANCE: Imaging study did not show clinical benefit. Raible, Eric // Cardiology Today;Feb2008, Vol. 11 Issue 2, p19 

    The article provides information on the initial result of the Effect of Combination Ezetimibe and High-Dose Simvastatin versus Simvastatin Alone on Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) clinical trial. Result shows that ezetimibe drug failed to reduce the risk of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics